Search PubMed⌕ Search

Biomedical subjects

B Otnes

Publications and source records attributed to B Otnes.

At least 37 records · Page 2Linked to original sources

Observations on urinary stone weight correlated with composition.

The weight of 500 upper urinary tract stones is correlated here with qualitative and quantitative stone analysis findings. The average weight was 725 mg, but 65% of the stones weighed less than 200 mg. With increasing weight, a shift in dominance from calcium oxalate to triple phosphate occurs. Stone materials differ in weight distribution, and reports of composition in different weight ranges may facilitate comparison and compensate for bias in selection of stones for analysis. Quantitative observations on stones consisting of calcium oxalate mono- and dihydrate with apatite show that the proportions of these components are much the same in all weight ranges, but vary with the composition of the nucleus. This is taken to support the significance of apatite in such stones and to indicate that stones with different nuclei should be considered separately. Similar observations on pure calcium oxalate stones may support a primary role of calcium oxalate monohydrate in the deposition of many such stones. Weight data for bladder stones are presented briefly and show a wide range of weights for all types of composition.

Calcium Oxalate↗

Sex differences in the crystalline composition of stones from the upper urinary tract.

Stones from the upper urinary tract of 172 male and 73 female patients have been analyzed by X-ray diffraction. Pure calcium oxalate stones contribute 39.5% of all stones from men, but only 6.9% of stones from women. This difference is consistent both above and below 50 years of age and largely independent of whether patients with known causes of stone formation are excluded. Other sex differences, such as a greater tendency to pure calcium phosphate and triple phosphate stones in female patients, are to a large extent dependent on demonstrable causes. The possibility of analysis error is discussed, considering the possibility of minor amounts of calcium phosphate being overlooked in "pure" calcium oxalate stones. Although this possibility cannot be rejected, there will still be a definite male preponderance of calcium oxalate stones with no or minimal admixture of calcium phosphate.

Calcium Oxalate↗

Method and reliability of crystallographic stone analysis.

The methods of daily routine analysis of urinary stones in one laboratory, employing a combination of microscopy, spectroscopy, chemistry, and X-ray diffractometry, are described. A methodologic study indicates that these methods are complementary and no one method is sufficient. Quantitative estimates are in general best obtained by X-ray diffraction, whereas qualitative identification of depositional sequence and the quantitative determination of minor constituents must depend on microscopic and chemical methods. Components at a concentration of 1 per cent may be identified whereas those in excess of 5 per cent are rarely overlooked. Concentrations are correct within +/- 10 per cent of stone mass.

Calcium Oxalate↗

A morphological study on the effect of cyproterone acetate on human prostatic carcinoma.

Sixteen patients with prostatic carcinoma were treated with 200 mg of Cyproterone acetate daily. No other kind of hormonal treatment was given. Transrectal biopsies of the prostate were taken before the treatment was started, and at regular intervals afterwards. The treatment period lasted from 3 to 16 months, with an average of 9 months. A thorough examination of multiple sections from all specimens revealed no convincing signs of cellular involution. The study has demonstrated no specific or significant atrophic changes following Cyproterone acetate therapy. Some possible explanations regarding the effect of Cyproterone acetate on human malignant prostatic tissue are discussed.

Adenocarcinoma↗

Probable endometrial carcinoma of the prostate, crossed renal ectopia and dermatomyositis in a 32-year-old man.

An unusual type of prostatic carcinoma associated with crossed renal ectopia and dermatomyositis is reported in a young man. Infiltration by an epithelial tumor filled the enlarged prostate with soft papillary masses. Cystoprostatectomy and removal of a single large pelvic lymph node metastasis were done. Histologically, the tumor resembled endometrial carcinoma and may have arisen from paramesonephric tissue in the prostate. Large amounts of immunoglobulins were found in the tumor tissue. The patient has survived for more than 5 years, although a slow growing urethral recurrence has been noted.

Adenocarcinoma↗

Treatment of prostatic carcinoma with cyproterone acetate.

Sixteen patients with prostatic carcinoma were treated with 200 mg of Cyproterone acetate daily. No other kind of hormonal treatment was administered. Increasing skeletal metastases were observed in 6 patients, whereas significant reduction of metastases took place in 2 patients. Objective relief of stranguria was observed only in 3 patients. The amount of residual urine increased in 3 patients and was reduced in 5. In about one third of the patients, the prostate gland became smaller and softer. The acidic phosphatases decreased from pathological to normal values in 7 patients. There were no observed hepatic, renal or haemotological side-effects. However, serious cardio-vascular complications occurred in 6 patients, while arterial hypertension developed in 4. It is suggested that Cyproterone acetate cannot be recommended as the only kind of hormonal treatment of prostatic cancer.

Acid Phosphatase↗

Comparison of radiological measurement and actual size of ureteral calculi.

100 ureteral calculi were measured on X-ray films and directly on the stone after passage or removal. The largest diameters were compared. The size of the stone was radiologically overestimated for 59 stones, correct for 26 and underestimated for 15. 73 of the stones were radiologically measured within +/-25% of the actual size.

Evaluation Studies as Topic↗

A comparison between urography and radioisotope renography in the follow-up of surgery for hydronephrosis.

The result of surgical correction of hydronephrosis caused by chronic obstruction at the pyeloureteral junction has been evaluated clinically as well as by urography and body background substracted renography performed preoperatively and up to 65 months postoperatively. The average follow-up period was 24 months. Twenty-eight patients (29 kidneys) were operated. Clinically 24 patients were improved. Urography showed regress of hydronephrosis and/or improved urinary pelvic drainage in 22 patients, whereas kidney function is judged from renography was improved in only 8 patients. Improvement in all parameters was generally most marked during the first postoperative months. Renographic improvement was seen much more often when the contralateral (non-operated) kidney was abnormal. Thus, kidney function in terms of effective renal plasma flow is rather uninfluenced by hydronephrosis surgery if the contralateral kidney is normal, whereas clinical improvement in urinary drainage is regularly obtained. This improvement in drainage is poorly registered by renography. It is concluded that renography is an important complementary method to urography, but the method cannot replace the radiological methods in the follow-up of hydronephrosis surgery.

Adolescent↗

Doxycycline levels in prostatic tissue and blood.

Doxycycline was administered orally to 23 patients scheduled for prostatectomy or radical cystectomy. Blood and prostatic tissue samples were collected simultaneously during operation and subsequently assayed for doxycycline levels. The concentration of doxycycline in the prostatic tissue was on average 2.75 mug/g which is far above the therapeutic level. The lowest level recorded was 0.85 mug and the highest was 4.81 mug. The findings suggest a tendency for this antibiotic to accumulate in prostatic tissue. This is in agreement with the clinical observations of the good effect of doxycycline treatment in patients with chronic bacterial prostatitis.

Administration, Oral↗